



SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE 1ST HALF YEAR ENDED 30 JUNE 2023

CHARACTERISTICS OF THE LEAP MARKET OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

THE LEAP MARKET HAS BEEN POSITIONED AS A MARKET DESIGNED TO ACCOMMODATE CORPORATIONS TO WHICH A HIGHER INVESTMENT RISK MAY BE ATTACHED THAN OTHER CORPORATIONS LISTED ON THE ACE MARKET OR MAIN MARKET OF BURSA SECURITIES. IT IS A QUALIFIED MARKET WHICH IS MEANT MAINLY FOR SOPHISTICATED INVESTORS ONLY. ONLY EXISTING SECURITIES HOLDERS AND SOPHISTICATED INVESTORS ARE ALLOWED TO PARTICIPATE IN CORPORATE EXERCISES UNDERTAKEN BY SUPERGENICS BERHAD (“SGBHD” OR THE “COMPANY”). SOPHISTICATED INVESTORS SHOULD BE AWARE OF THE POTENTIAL RISKS OF INVESTING IN SUCH CORPORATIONS AND SHOULD MAKE THE DECISION TO INVEST ONLY AFTER DUE AND CAREFUL CONSIDERATION.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2023

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

| | INDIVIDUAL 6 Months Ended | | CUMULATIVE Year To Date | |
|---|------------------------------|-----------------------|----------------------------|-----------------------|
| | 30 Jun 2023 RM'000 | 30 Jun 2022 RM'000 | 30 Jun 2023 RM'000 | 30 Jun 2022 RM'000 |
| Revenue | 4,490 | 5,030 | 4,490 | 5,030 |
| Cost of sales | (2,780) | (3,532) | (2,780) | (3,532) |
| Gross profit | 1,710 | 1,498 | 1,710 | 1,498 |
| Other operating income | 362 | 92 | 362 | 92 |
| Operating and administrative expenses | (1,705) | (1,340) | (1,705) | (1,340) |
| Share of associate's results | - | - | - | - |
| Profit from operations | 367 | 250 | 367 | 250 |
| Finance costs | (206) | (182) | (206) | (182) |
| Profit before taxation | 161 | 68 | 161 | 68 |
| Taxation | (114) | (14) | (114) | (14) |
| Total comprehensive profit | 47 | 54 | 47 | 54 |
| Total comprehensive profit attributable to : | | | | |
| Owners of the parent | 47 | 54 | 47 | 54 |
| | 47 | 54 | 47 | 54 |
| Earning per-share | sen | sen | sen | sen |
| Basic | 0.05 | 0.06 | 0.05 | 0.06 |
| Diluted | N/A | N/A | N/A | N/A |

The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive income should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2023**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

| | (UNAUDITED) As At 30 Jun 2023 RM'000 | (AUDITED) As At 31 Dec 2022 RM'000 |
|-------------------------------------|---|---|
| ASSETS | | |
| NON-CURRENT ASSETS | | |
| Property, plant and equipment | 4,545 | 4,180 |
| Right-of-use assets | 945 | 1,366 |
| Investment in associate | 179 | 179 |
| Intangible asset | 57 | 60 |
| Contract assets | 168 | 310 |
| Deferred tax assets | 32 | 32 |
| | 5,926 | 6,127 |
| CURRENT ASSETS | | |
| Inventories | 10 | 10 |
| Trade receivables | 6,732 | 7,643 |
| Other receivables | 782 | 442 |
| Other financial assets | 172 | 58 |
| Contract assets | 445 | 141 |
| Contract costs | 701 | 701 |
| Tax recoverable | 30 | 86 |
| Cash and bank balances | 996 | 280 |
| | 9,868 | 9,361 |
| TOTAL ASSETS | 15,794 | 15,488 |
| EQUITY | | |
| Share capital | 6,302 | 6,302 |
| Merger reserve | (1,450) | (1,450) |
| Retained earnings | 237 | 190 |
| Total Equity | 5,089 | 5,042 |
| LIABILITIES | | |
| NON-CURRENT LIABILITIES | | |
| Deferred tax liabilities | - | - |
| Lease liabilities | 1,155 | 1,104 |
| Bank borrowings | 2,576 | 2,801 |
| | 3,731 | 3,905 |
| CURRENT LIABILITIES | | |
| Trade payables | 1,155 | 3,447 |
| Other payables | 3,539 | 766 |
| Contract liabilities | 632 | 1,037 |
| Amount owing to directors | 15 | - |
| Lease liabilities | 267 | 367 |
| Bank borrowings | 1,366 | 882 |
| Provision for taxation | - | 42 |
| | 6,974 | 6,541 |
| TOTAL LIABILITIES | 10,705 | 10,446 |
| TOTAL EQUITY AND LIABILITIES | 15,794 | 15,488 |
| NET ASSETS PER-SHARE (RM) | 0.055 | 0.054 |

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2023

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

| GROUP | ATTRIBUTABLE TO THE OWNERS OF THE PARENT | | | TOTAL EQUITY RM'000 |
|---|---|---------------------------------|-------------------------------------|-------------------------------|
| | Non-distributable | | Distributable | |
| | Share Capital RM'000 | Merger Reserve RM'000 | Retained Earnings/ RM'000 | |
| As at 1 Jan 2023 | 6,302 | (1,450) | 190 | 5,042 |
| Profit for the financial period, representing total comprehensive income for the financial period | - | - | 47 | 47 |
| As at 30 Jun 2023 | 6,302 | (1,450) | 237 | 5,089 |
| As at 1 Jan 2022 | 6,302 | (1,450) | (156) | 4,696 |
| Profit for the financial year, representing total comprehensive income for the financial year | - | - | 346 | 346 |
| As at 31 Dec 2022 | 6,302 | (1,450) | 190 | 5,042 |

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))
(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1ST HALF YEAR ENDED 30 JUNE 2023**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

| | 6 Months Ended 30 Jun 2023 (UNAUDITED) | 12 Months Ended 31 Dec 2022 (AUDITED) |
|--|---|--|
| | RM'000 | RM'000 |
| CASH FLOW FROM OPERATING ACTIVITIES | | |
| Profit before taxation | 161 | 771 |
| Adjustments for: | | |
| Depreciation of property, plant and equipment | 666 | 571 |
| Depreciation of right-of-use asset | 104 | 303 |
| Gain on disposal of property, plant and equipment | - | (49) |
| Impairment loss on trade receivables | - | (36) |
| Share of associate's results | - | 63 |
| Interest expenses | 206 | 357 |
| Interest income | (1) | - |
| Fair value gain on financial assets at fair value through profit and loss | (14) | (2) |
| Operating profit before working capital changes | 1,122 | 1,978 |
| Changes in working capital: | | |
| Increase in inventories | - | (10) |
| Trade & other receivables | (298) | (2,668) |
| Trade & other payables | 526 | 688 |
| Amount owing from associate | - | - |
| Contract assets & liabilities | 303 | 369 |
| Contract costs | - | (187) |
| Amount owing to director | (29) | - |
| | 502 | (1,808) |
| Cash generated from operations | 1,624 | 170 |
| Interest paid | - | - |
| Interest received | 15 | - |
| Tax paid | (100) | (190) |
| | (85) | (190) |
| Net cash generated from/(used in) operating activities | 1,539 | (20) |
| CASH FLOW FROM INVESTING ACTIVITIES | | |
| (Additional)/Withdrawal in other investment | (114) | 21 |
| Addition in intangible asset | - | (60) |
| Amortise in intangible asset | 3 | - |
| Purchase of property, plant and equipment | (715) | (358) |
| Proceed from disposal of property, plant and equipment | - | 49 |
| Deposit received from disposal of plant and equipment | - | 200 |
| Investment in an associate | - | (242) |
| Net cash used in investing activities | (826) | (390) |
| CASH FLOW FROM FINANCING ACTIVITIES | | |
| Interest paid | (206) | (357) |
| Drawdown of borrowings | 1,329 | 570 |
| Repayment of borrowings | (797) | (1,663) |
| Repayment of lease liabilities | (49) | (320) |
| Net cash generated from/(used in) financing activities | 277 | (1,770) |
| Net increase/(decrease) in cash and cash equivalents | 990 | (2,180) |
| Cash and cash equivalents at beginning of the period/year | 6 | 2,186 |
| Cash and cash equivalents at end of the period/year | 996 | 6 |
| CASH AND CASH EQUIVALENTS AT END OF THE PERIOD/YEAR COMPRISES: | | |
| Cash and bank balances | 996 | 6 |

The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

PART A: EXPLANATORY NOTES IN COMPLIANCE WITH MALAYSIAN FINANCIAL REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING

A1) Basis of preparation

This interim financial statements have been prepared under the historical cost convention. This interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards (“MFRS”) 134: Interim Financial Reporting and as well as Rule 6.12 and Appendix 6A of the LEAP Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”).

The interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2022 and the accompanying explanatory notes attached to this interim financial report.

A2) Significant accounting policies and application of MFRS

The accounting policies adopted are consistent with those of the previous financial year except the amendments to following accounting standards that are effective for the Group's financial year beginning on or after 1 Jan 2023:-

| Description | Effective for annual periods beginning on or after |
|--|---|
| MFRS 17: Insurance Contracts Amendments to MFRS 17: Insurance Contracts | 1 Jan 2023 |
| Amendments to MFRS 112: Deferred tax related to Assets and Liabilities arising from a single transaction | 1 Jan 2023 |



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

A2) Significant accounting policies and application of MFRS (Cont'd)

The above amendments to accounting standards effective during the financial year do not have any significant impact on the interim financial report of the Group.

As at the date of authorisation of this Condensed Report, the following accounting Standards and amendments to accounting Standards have been issued by the Malaysian Accounting Standards Board ("MASB") but are not yet effective:-

| Description | Effective for annual periods beginning on or after |
|--|---|
| Amendments to MFRS16: Lease Liability in a Sale and Leaseback | 1 Jan 2024 |
| Amendments to MFRS101 Presentation of Financial Statements – Classification of Liabilities as Current or Non-current | 1 Jan 2024 |
| Amendments to MFRS107 and MFRS7: Supplier Finance Arrangements | 1 Jan 2024 |

Effective date of these Amendments to Standards has been deferred, and yet to be announced:-

Amendments to MFRS 10 Consolidated Financial Statements and MFRS 128 Investments in Associates and Joint Venture – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

The above pronouncements are either not relevant or do not have any impact on the financial statements of the Group.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

A3) Seasonal or cyclical factors

The Group's performance is not significantly affected by seasonal and cyclical factors.

A4) Unusual items

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the reporting period under review.

A5) Material changes in estimates

There were no significant changes in the nature and amount of estimates reported in the prior interim period of the current financial period or prior years that have a material effect on the current financial period ended 30 June 2023 under review.

A6) Debt and equity securities

There were no issuance or repayment of debt and equity securities, share buy-backs, share cancellations, share held as treasury shares by the Group during the financial period.

A7) Segmental reporting

The Group's segmental report for the current financial period ended 30 June 2023 under review are as follows:-

Revenue by Business Activities

| | Individual 6 Months Ended | | Cumulative Year To Date | |
|---|------------------------------|-----------------------|----------------------------|-----------------------|
| | 30 Jun 2023 RM'000 | 30 Jun 2022 RM'000 | 30 Jun 2023 RM'000 | 30 Jun 2022 RM'000 |
| <u>REVENUE</u> | | | | |
| Provision of integrated turnkey solutions | 2,152 | 4,145 | 2,152 | 4,145 |
| Provision of maintenance services | 525 | 479 | 525 | 479 |
| Laboratory Services | 1,813 | 406 | 1,813 | 406 |
| Total consolidated revenue | 4,490 | 5,030 | 4,490 | 5,030 |



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

A8) Valuation of property, plant and equipment

There was no valuation on any of the Group's property, plant & equipment during the reporting period ended 30 June 2023.

A9) Significant events

There were no events of a material nature to be disclosed in the interim financial statements for the current financial period ended 30 June 2023.

A10) Material changes in the composition of the Group

During the reporting period, the Company incorporated two new wholly-owned subsidiary, Supergenics Global Sdn Bhd and Supergenics Bio Agro Sdn Bhd with same issued share capital of RM100 on 21 July 2023 and 29 August 2023 respectively.

A11) Contingent liabilities and contingent assets

There were no material contingent liabilities or assets for the reporting period ended 30 June 2023.

A12) Material events subsequent to the end of the interim financial report

The management is not aware of any material events subsequent to the end of the interim financial report that have not been reflected in the financial statements for the current financial report ended 30 June 2023 under review.

A13) Capital commitment

There was no commitment for the purchase of property, plant and equipment provided for in the current financial report ended 30 June 2023.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

PART B: ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1) Review of performance

(i) 1st Half Year, FY 2023 (“H1FY2023”) vs 1st Half Year, FY 2022 (“H1FY2022”)

| | INDIVIDUAL | | | CUMULATIVE | | |
|-------------------------------|----------------|-------------|----------|--------------|-------------|----------|
| | 6 Months Ended | | Variance | Year To Date | | Variance |
| | 30 Jun 2023 | 30 Jun 2022 | % | 30 Jun 2023 | 30 Jun 2022 | % |
| | RM'000 | RM'000 | % | RM'000 | RM'000 | % |
| Revenue | 4,490 | 5,030 | (10.7) | 4,490 | 5,030 | (10.7) |
| Gross profit | 1,710 | 1,498 | 14.1 | 1,710 | 1,498 | 14.1 |
| Profit/(Loss) before taxation | 161 | 68 | 136.8 | 161 | 68 | 136.8 |

For the current financial period under review, the Group posted a revenue of RM4.49 million as compared to its corresponding preceding financial period, H1FY2022 of RM5.03 million. The revenue has reduced mainly due to some projects are at the final phase of the project's lifecycle which contributing lower revenue to the Company during the financial period ended. Nonetheless, the increase in the revenue from both maintenance and laboratory services has mitigate the impact from the reduced revenue in the project-based income.

In line with the increase in revenue in both maintenance and laboratory services, the Group had improved its performance by increasing the profit before taxation during the current period, whereby the Group has recorded profit before taxation of RM0.16 million as compared to its corresponding preceding financial period, H1FY2022 profit before taxation of RM0.07 million.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

B1) Review of performance (Cont'd)

(ii) Changes in revenue and PBT for H1FY2023 as compared with the immediate preceding period ended 31 Dec 2022 (“H2FY2022”)

| | Current 6 Months Ended 30 Jun 2023 | Immediate 31 Dec 2022 | Variance |
|-------------------------------|---|----------------------------------|-----------------|
| | RM'000 | RM'000 | % |
| Revenue | 4,490 | 5,686 | (21.0) |
| Gross profit | 1,710 | 2,281 | (25.0) |
| Profit/(Loss) before taxation | 161 | 550 | (70.8) |

The Group has recorded revenue of RM4.49 million with profit before tax of RM0.16 million for the 1st half year ended 30 June 2023 as compared to the immediate preceding half year which recorded revenue of RM5.69 million and profit before tax of RM0.55 million. The reduce in gross profit margin mainly contributed by the lower revenue in the provision of integrated turnkey solutions segment.

B2) Future prospects

The Malaysian economy expanded moderately in the second quarter of 2023 (2.9%; 1Q 2023: 5.6%), weighed mainly by slower external demand. Domestic demand remained the key driver of growth, supported by private consumption and investment. Household spending was supported by further growth in employment and wages. Meanwhile, investment activity was underpinned by capacity expansion, progress of multi-year projects and higher fixed asset spending by the government. Continued recovery in inbound tourism partially offset the slower goods export growth. Growth during the quarter was also affected by the high base effect in the second quarter of 2022 when the economy experienced strong growth from reopening effects and policy measures. On the supply side, the services and construction sectors continued to support growth. Meanwhile, production in the agriculture and mining sectors were affected by hot weather and plant maintenance. On a quarter-on-quarter seasonally-adjusted basis, the economy grew by 1.5% (1Q 2023: 0.9%).



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

B2) Future prospects (Cont'd)

Headline inflation during the quarter continued to moderate to 2.8% (1Q 2023: 3.6%). The moderation was recorded in both non-core inflation and core inflation. For non-core inflation, fresh food and fuel contributed to the decline. Core inflation, while declining, remained elevated relative to its long-term average (2011-2019 average: 2.0%). The moderation in core inflation (2Q 2023: 3.4%; 1Q 2023: 3.9%) was largely contributed by selected services. These included food away from home, telephone and telefax services, and personal transport repair and maintenance. Inflation pervasiveness declined as the share of Consumer Price Index (CPI) items recording monthly price increases moderated to 42.7% during the quarter (1Q 2023: 56.0%), below the second quarter long-term average (2011-2019) of 43.9%. Notably, inflation pervasiveness dropped in June after a transitory uptick in May following the festive season.

In line with expectations, headline inflation has continued to moderate to 2.8% in 2Q 2023 from the peak of 4.5% in 3Q 2022 amid lower cost factors. While core inflation has also moderated, it has been more persistent and remains elevated relative to the long-term average, amid lingering demand and cost factors. For the second half of 2023, both headline and core inflation are projected to trend lower within expectations, partly due to the higher base in the corresponding period last year. Nonetheless, risks to the inflation outlook remain subject to the changes to domestic policy on subsidies and price controls, as well as global commodity prices and financial market developments.

For the second half of 2023, the Malaysian economy is expected to expand at a moderate pace. Slower external demand will continue to weigh on economic activity particularly for the export-oriented sectors. Growth will be supported by domestic demand, underpinned by favourable labour market conditions, particularly in the domestic-oriented sectors. Tourist arrivals is expected to continue improving, thereby lifting tourism activities, while investment activity would be supported by implementation of multi-year investment projects. Domestic financial conditions also remain conducive to financial intermediation. While the growth outlook is subject to some downside risks stemming from weaker-than-expected global growth, upside risks mainly emanate from domestic factors such as stronger-than expected tourism activity and faster implementation of projects.

(Source: Economic and Financial Developments in Malaysia in the Second Quarter of 2023 and BNM Quarterly Bulletin Vol.38 No. 2, Second Quarter 2023)



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

B2) Future prospects (Cont'd)

The Group will continue to expand its geographical reach and targets to secure cleanrooms development projects as well as the provision of management services for cleanrooms in Penang and Johor Bahru. The outstanding order book of the Group now stands at RM12.48 million. In addition, the Group intends to further capitalise on its Supergenics' Laboratory Monitoring and Control System, an in-house developed proprietary system which allows users to control, maintain and monitor indoor air quality and performance of cleanrooms. The Group anticipates an increase in demand for its cleanroom development solutions as the SGMP provides customers with increased flexibility in installation at lower costs compared to traditional construction methods.

In addition to the Group's traditional business operations mentioned above, its expansion into its Regenerative Treatment Segment is expected to bode well for the future prospects of the Group. Since the FYE 2021, the Group has managed to generate revenue from this segment and has seen the said revenue generated more than doubled in the FYE 2022. The Group may further expand its Regenerative Treatment Segment by engaging in partnerships with service providers involved in the health, wellness or aesthetic industries to further improve the sales of the products under this segment. Premised on the outlook of the Regenerative Treatment Segment, the management of Supergenics believes this segment is rapidly growing and views it favourably as a potential driver in the Group's future growth.

B3) Profit forecast, Profit Guarantee and Internal Targets

The group has not issued any profit forecast, profit guarantee in any form of public documentation and announcement.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

PART C: OTHER INFORMATION

C1) Status of Corporate Proposal

Save as disclosed below, there were no other corporate proposals announced but pending completion as at the date of this report :-

- i) Proposed private placement of up to 26,000,000 new ordinary shares in Supergenics ("Shares"), representing approximately 27.96% of the existing total number of issued shares at an issue price to be determined and announced later ("Placement Shares") ("Proposed Private Placement") ; and
- ii) Proposed diversification of the principal activities of Supergenics and its subsidiaries ("Supergenics Group" or the "Group") to include the provision of administrative health care services, operating of medical laboratories and developing of medical treatment and regenerative treatment products ("Regenerative Treatment Segment") ("Proposed Diversification")

C2) Material Litigation

The management is not aware of any pending material litigation which will have a material effect on the financial position or the business of the Group and the Board is not aware of any proceedings pending or threatened against the Group or of any fact likely to give rise to any proceedings which may materially and adversely affect the financial position or business of the Group at the date of this report.

C3) Dividends

No dividend has been declared by the Group since the end of the previous financial year. The Board of Directors do not recommend any dividend in respect of the current financial period under review.

C4) Utilisation of Proceeds

There were no any utilization of proceed during the reporting period ended 30 June 2023.



NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 1st HALF YEAR ENDED 30 JUNE 2023

C5) Earnings per share

| | Individual 6 Months Ended | | Cumulative Year To Date | |
|--|------------------------------|--------------|----------------------------|--------------|
| | 30 June 2023 | 30 June 2022 | 30 June 2023 | 30 June 2022 |
| a) <u>Basic earnings per-share</u> | | | | |
| Profit attributable to the owners of parent ('000) | 47 | 54 | 47 | 54 |
| Total weighted average number of ordinary shares in issue ('000) | 93,000 | 93,000 | 93,000 | 93,000 |
| Basic earning per share (sen) | 0.05 | 0.06 | 0.05 | 0.06 |
| b) <u>Diluted earnings per-share</u> | N/A | N/A | N/A | N/A |

C6) Authorisation for issue

The interim financial report were authorised for issue by the Board of Directors in accordance with resolution of the directors on 30 August 2023.